Category: Federal Forum Posters
Purpose: The introduction of Direct Acting Antiviral (DAA) therapy has produced several therapy options for Hepatitis C (HCV) management; as such, accompanying factors including drug interactions, adverse effect profiles, and pharmacological cost now exist. Further, considering potential resource conservation, assimilating management of less complicated cases into the domain of primary care practice is appealing. The Nuka System of Care at Southcentral Foundation (SCF) encompasses an interdisciplinary approach to primary care, allowing unique opportunities for pharmacists. This project details the evolving role of clinical pharmacists as members of a primary care team approach to provision of HCV DAA therapy for treatment-naïve patients.
Methods: This quality improvement project involves outlining the transition of HCV DAA therapy management from a specialty hepatitis clinic to an ambulatory primary care center (PCC). Descriptive data will detail: the development of a workflow outlining the PCC process from time of HCV diagnosis to treatment completion; management and monitoring guidelines for clinical pharmacists; electronic health record (EHR) documentation; development of educational tools for integrated care teams (pharmacists, practitioners, nursing, case managers, etc.); third-party billing procedures; and cost implications. Feedback from integrated care team members will address concerns and level of comfort with assumption of HCV treatment in their respective ambulatory clinic. Results are expected to ensure assimilation of HCV DAA therapy into the primary care setting, improving access to care and customer-owner (patient) outcomes in the Alaska Native/American Indian population served by SCF.
Results: not applicable
Conclusion: not applicable
Matthew Begay-Bruno– PGY1 Pharmacy Resident, Southcentral Foundation, Anchrorage, AK